Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Drop in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large decrease in short interest in April. As of April 15th, there was short interest totalling 165,200 shares, a decrease of 22.7% from the March 31st total of 213,800 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 81,400 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Investors Weigh In On Senti Biosciences

A number of hedge funds have recently made changes to their positions in the company. TD Asset Management Inc increased its position in shares of Senti Biosciences by 88.4% during the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after purchasing an additional 113,172 shares in the last quarter. ARK Investment Management LLC increased its position in shares of Senti Biosciences by 7.9% during the 4th quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after purchasing an additional 143,785 shares in the last quarter. Finally, 8VC GP I LLC acquired a new stake in shares of Senti Biosciences during the 4th quarter worth about $1,675,000. Institutional investors and hedge funds own 25.73% of the company’s stock.

Senti Biosciences Stock Performance

Shares of SNTI stock traded up $0.05 during mid-day trading on Tuesday, reaching $0.36. The company’s stock had a trading volume of 2,388,760 shares, compared to its average volume of 132,253. Senti Biosciences has a 1-year low of $0.27 and a 1-year high of $1.10. The company has a market cap of $16.47 million, a P/E ratio of -0.23 and a beta of 2.96. The firm’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.41.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative net margin of 2,692.82% and a negative return on equity of 74.59%. Sell-side analysts anticipate that Senti Biosciences will post -1 EPS for the current year.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.